false0001703647NASDAQ00017036472024-05-132024-05-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2024

 

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39062

47-2324450

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

One Kendall Square, Building 600-700, Suite 6-401

Cambridge, MA

 

02139

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 468-1999

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

KRRO

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01. Other Events.

Effective May 13, 2024, Dr. Kemi Olugemo, M.D., FAAN, joined Korro Bio, Inc., or Korro, as its Chief Medical Officer.

Prior to joining Korro, Dr. Olugemo, age 48, served as Vice President of Global Clinical Development at Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) from December 2022 to May 2024. Prior to this role, she served as Head of Clinical Development at Laronde, Inc. (now Sail Bio, Inc.) from November 2021 to December 2022 and as Executive Director of Clinical Development at Ionis Pharmaceuticals Inc. (Nasdaq: IONS) from November 2019 to November 2021. Dr. Olugemo also served as Senior Director of Global Therpeutic Area Head, Neuroscience at Parexel International Corp from June 2014 to November 2019. Dr. Olugemo led clinical development and operations for multiple global programs in rare and common diseases across an array of therapeutic areas, resulting in approvals in global markets. Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and completed her Neurology Residency there. Dr. Olugemo also completed an additional Fellowship in Neuroimmunology & Multiple Sclerosis at the Maryland Center for Multiple Sclerosis. She holds a B.S. in clinical laboratory science from the University of Massachusetts.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KORRO BIO, INC.

 

 

Date: May 14, 2024

By:

/s/ Ram Aiyar

 

 

 

 

Name:

Ram Aiyar

 

Title:

President and Chief Executive Officer

 

 

v3.24.1.1.u2
Document and Entity Information
May 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2024
Entity Central Index Key 0001703647
Entity File Number 001-39062
Entity Registrant Name Korro Bio, Inc.
Entity Incorporation State Country Code DE
Entity Tax Identification Number 47-2324450
Entity Address Address Line One One Kendall Square
Entity Address, Address Line Two Building 600-700
Entity Address, Address Line Three Suite 6-401
Entity Address City Or Town Cambridge
Entity Address Postal Zip Code 02139
Entity Address State Or Province MA
City Area Code (617)
Local Phone Number 468-1999
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol KRRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Korro Bio Charts.
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Korro Bio Charts.